Potential of phosphodiesterase type IV inhibitors in the treatment of rheumatoid arthritis

IDrugs

Volumn 1, Issue 5, 1998, Pages 541-553

  Souness, John E ^a   Foster, Martyn ^a  

^a Discovery Biology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001760048     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Palfreyman MN, Souness JE: Phosphodiesterase type IV inhibitors. Prog Med Chem (1996) 33:1-52.
2. Beavo JA, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci (1990) 11:150-155.
3. DeBrito FB, Souness JE, Wame PJ: Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. Emerging Drugs (1997) 2:249-268.
4. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS: An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol (1995) 22:625-629.
5. Pincus T, Callahan LF: What is the natural history of rheumatoid arthritis? Rheum Dis Clin N Am (1993) 19:123-151.
6. Freemont AJ: Histopathology of the rheumatoid joint. In: Mechanisms and models in rheumatoid arthritis (1995). Henderson B, Edwards JCW, Pettiper ER (Eds) Academic Press, 83-113.
7. Müller-Ladner U: Molecular and cellular interactions in the rheumatoid synovium. Curr Opin Rheumatol (1996) 8:210-220.
8. Henderson B, Pettifer ER: Arthritogenic actions of recombinant IL-1 and TNFα in the rabbit. Clin Exp Immunol (1989) 75:306-310.
9. Buckland-Wright JC, Lynch JA, Bird C: Microfocal techniques in quantitative radiography: measurement of cancellous bone organisation. Br J Rheumatol (1996) 35:(Suppl. 3) 18-22.
10. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T: Quantitative histologic studies on the pathogenesis of peri-articular osteoporosis in rheumatoid arthritis. Arthritis Rheum (1985) 28:25-31.
11. Chikanza IC, Fernandez L: Recent developments in the treatment of rheumatoid arthritis with targeted biological agents. Emerging Drugs (1997) 2:269-286.
12. Conaghan PG, Brooks P: Disease-modifying anti-rheumatic drugs. Curr Opin Rheumatol (1996) 8:176-182.
13. Weinblatt ME, Kaplan H, Gennain BF, Block S, Soloman SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E, Torretti D, Weissman B: Methotrexate in rheumatoid arthritis. A five year prospective, multi-centre study. Arthritis Rheum (1994) 37:1492-1498.
14. Pincus T: The paradox of effective therapies, but poor long-term outcomes in rheumatoid arthritis. Arthritis Rheum (1992) 21:2-15.
15. Kirwan JR: Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. New Engl J Med (1995) 333:142-146.
16. Weisman MH: Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheumatol (1996) 8:188-194.
17. Cooper C, Coupland C, Mitchell M: Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis (1995) 54:49-52.
18. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Shirrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK, Johnston JM: Campath-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. Arthritis Rheum (1995) 38:1589-1594.
19. van der Lubbe PA, Dijkmans BAC, Markusse HM, Nassander U, Breedveld FC: A randomised double-blind placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum (1995) 38:1097-1106.
20. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, MacFarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110.
21. Bloxham DP: Therapeutic applications of anti-TNF monoclonal antibodies. Exp Opin Invest Drugs (1994) 3:907-912.
22. Badger AM, Lee JC: Advances in antiarthritic therapeutics. Drug Discovery Today (1997) 2:427-435.
23. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumour necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 34:1125-1132.
24. Le J, Vilcek J: Biology of disease. Tumour necrosis factor and interleukin 1: Cytokines with multiple overlapping biological activities. Lab Invest (1987) 56:234-248.
25. Webb GR, Westacott CI, Elson CJ: Chondrocyte tumour necrosis factor receptors and focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage (1997) 5:422-437.
26. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson J-A: Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol (1996) 118:649-658.
27. Semmler J, Wachtel H, Endres S: The selective Type IV phosphodiesterase inhibitor rolipram suppresses tumour necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol (1993) 15:409-413.
28. Molnar-Kimber K, Yonno L, Heaslip RJ, Weichman BM: Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions (1993) 39:C77-C79.
29. Seldon PM, Barnes PJ, Meja K, Giembycz MA: Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase. Mol Pharmacol (1995) 48:747-757.
30. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yamell DP, Taylor JD, Furdon PJ: Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther (1995) 272:1313-1320.
31. Schade FU, Schudt C: The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumour necrosis factor by macro-phages. Eur J Pharmacol (1993) 230:9-14.
32. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G: Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J Immunol (1995) 155:4909-4916.
33. Ochalski SJ, Hartman DA, Belfast MT, Walter TL, Glaser KB, Carlson RP: Inhibition of endotoxin-induced hypothermia and serum TNF-α levels in CD-1 mice by various pharmacological agents. Agents Actions (1993) 39:C52-C54.
34. Cheng JB, Watson JW, Showell HJ, Cohan VL, Turner CR, Turner CR: CP-80,633 elevates plasma cAMP levels and decreases TNF production in mice: Effect of adrenalectomy. J Allergy Clin Immunol (1995) 95:351.
35. Singh HN, Blancuzzi V, Greenwood S, Skiles JW, O'Byrne EM: Synovial fluid levels of tumour necrosis factor-α in the inflamed rat knee: Modulation by dexamethasone and inhibitors of matrix metalloproteinase and phosphodiesterase. Inflamm Res (1997) 46:(Suppl 2) S153-S154.
36. Jilg S, Barsig J, Leist M, Kusters S, Volk H-D, Wendel A: Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxic shock. J Pharmacol Exp Ther (1996) 278:421-431.
37. Souness JE: Role of PDE4 inhibitors in rheumatoid arthritis. William Harvey Research Conferences: Phosphodiesterase Enzymes: A growing family of drug targets, (1997) London, UK.
38. Lapadula G, Iannone F, Dell'Accio, F, Covelli M, Pipitone V: Interleukin-10 in rheumatoid arthritis. Clin Exp Rheumatol (1995) 13:629-632.
39. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldman M: Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 39:495-503.
40. Interleukin-10 DNAX Research Institute phase change 1, USA. R&D Focus Drug News 24 March 1997
41. Snyder DS, Beller DI, Unanue ER: Prostaglandins modulate macrophage la expression. Nature (1982) 299:163-165.
42. Frohman EM, Vayuvegula B, Gupta S, van den Noort S: Norepinephrine inhibits α interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via β2-adrenergic signal transduction mechanisms. Proc Natl Acad Sci USA (1988) 85:1292-1296.
43. Williams RO, Ghrayeb J, Feldman M, Maini RN: Succesful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology (1995) 84:433-439.
44. Souness JE, Houghton C, Sardar N, Withnall MT: Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase conformer. Br J Pharmacol (1997) 121:743-750.
45. Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, Polson JB: Multiple high-affinity cyclic AMP phosphodiesterases in human T-lymphocytes. Biochem Pharmacol (1991) 42:869-877.
46. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ: identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and biosynthesis of interleukin-2. Br J Pharmacol (1996) 118:1945-1958.
47. Pober JS, Slowik MR, De Luca LG, Ritchie AJ: Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J Immunol (1993) 150:5114-5123.
48. Ollivier V, Parry GCN, Cobb RR, de Prost D, Mackman N: Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem (1996) 271:20828-20835.
49. Ballestas ME, Benveniste EN: Elevation of cyclic AMP levels in astrocytes antagonizes cytokine-induced adhesion molecule expression. J Neurochem 69:1438-1448.
50. Lidington E, Nohammer C, Dominguez M, Ferry B, Rose ML: Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin Exp Immunol (1996) 104:66-71.
51. Raebum D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE, Karlsson J-A: Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol (1994) 113:1423-1431.
52. Suzuki K, Rapuno BE, Bockman RS: Role of protein kinase A in collagenase-1 gene regulation by prostaglandin E1: Studies in a rabbit synoviocyte cell line, HIG-82. J Bone Miner Res (1997) 12:561-567.
53. Boyle DL, Sajjadi FG, Firestein GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum (1996) 39:923-930.
54. Miyamoto K, Waki Y, Horita T, Kasugai S, Ohya K: Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol (1997) 54:613-617.
55. May LG, Gay CV: Parathyroid hormone uses both adenylate cyclase and protein kinase C to regulate acid production in osteoclasts. J Cell Biochem (1997) 65:565-573.
56. Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M, Suda T: Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology (1996) 137:4685-4690.
57. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A: Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest (1997) 99:2961-2970.
58. Da Silva Jardine P, Thompson D: Anti-osteoporosis agents. Ann Rep Med Chem (1996) 31:211-220.
59. Ahlstrom M, Lamberg-Allardt C: Rapid protein kinase A-mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. J Bone Miner Res (1996) 12:172-178.
60. 2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J Bone Miner Res (1996) 11:62-71.
61. Caverzasio J, Bonjour JP: Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Kidney Int (1996) 49:975-980.
62. Grumbles RM, Howell DS, Wenger L, Altman RD, Howard GA, Roos BA: Hepatocyte growth factor and its actions in growth plate chondrocytes. Bone (1996) 19:255-261.
63. Lowe GN, Fu YH, McDougall S, Polendo R, Williams A, Benya PD, Hahn TJ: Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Endocrinology (1996) 137:2208-2216.
64. 2+) - calmodulin regulated processes. J Cell Biochem (1997) 65:408-419.
65. 1 as inhibitors of the adjuvent-induced arthritis syndrome of rats. Ann Rheumatic Dis (1978) 37:212-217.
66. Sekut L, Yarnall D, Stimpson SA, Noel LS, Batemanfite R, Clark RL, Brackeen MF, Menius JA, Connolly KM: Antiinflammatory activity of phosphodiesterase (PDE) IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol (1995) 100:126-132.
67. Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L: Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram. Clin Exp Immunol (1997) 108:415-419.
68. Redford, J., Wicks, S., Webber, S. & Foster, M. (1998) Post-inflammatory osteoporosis in the rat streptococcal cell wall-induced arthritis model. Keystone Symposium, Pathogenesis of Rheumatoid Arthritis, Colorado, January 1998
69. Kasugai S, Otani K: Effect of phosphodiesterase IV inhibitors on bone tissue: A possibility for its use as a new agent to treat osteoporosis. Kobubyo Gakkai Zasshi (1996) 63:432
70. Chikanza IC: The neuroendocrine immunology of rheumatoid arthritis. Baillières Clin Rheum (1996) 10:273-293.
71. Kumari M, Cover PO, Poyser RH, Buckingham JC: Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: In vitro and in vivo studies. Br J Pharmacol (1997) 121:459-468.
72. Cheng JB, Watson JW, Pazoles CJ, Eskra JD, Griffiths RJ, Cohan VL, Turner, CR, Showell HJ. Pettipher ER: The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumour necrosis factor-α (TNFα) production in mice: Effect of adrenalectomy. J Pharmacol Exp Ther (1997) 280:621-626.
73. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL: Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA (1989) 86:2374-2378.
74. Chikanza IC, Jawed SJ, Blake DR, Perrot S, Menkes CJ, Barnes CG, Perry JD, Wright MG: Treatment of patients with rheumatoid arthritis with RP 73401 phosphodiesterase Type IV Inhibitor. Arthritis Rheum (1996) 39:S282.
75. Everitt DE, Boike S, Davies B, Zariffa N, Audet P, Brown L, Freed M, Ilson B, Esser K, O'Leary Bartus J, Slack G, Smith G, Jordasky D: Pharmacokinetics, tolerability and TNF inhibitory activity of 1,3-di(cyclopropyl-methyl)-8-aminoxanthine (BRL 61063). Clin Pharmacol Ther (1994) 55:150.
76. Zabel P, Schonharting MM, Wolter DT, Schade UF: Oxpentifylline in endotoxaemia. Lancet (1989) 8678: 1474-1477.
77. Heaslip RJ, Evans DY: Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol (1995) 286:281-290.
78. 3H] rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem (1996) 39:120-125.
79. Carpenter DO, Briggs DB, Knox AP, Strominger N: Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J Neurophys (1988) 59:358-369.
80. Puurunen J, Lucke C, Schwabe U: Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn-Schmiedeberg's Arch Pharmacol (1978) 304:69-75.
81. Muller T, Engels P, Fozard JR: Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci (1996) 17:294-298.
82. 2-stimulated cyclic AMP accumulation by lipopolysaccharide in murine peritoneal macrophages. J Biol Chem (1991) 266:10305-10312.
83. Souness JE, Rao S: A proposal for pharmacologically distinct conformers of PDE4. Cell Signalling (1997) 9:227-236.
84. Harbinson PL, Sullivan PJ, Wahid S, Kilfeather S, Page C, Heath P, Costello JF: Effect of CDP 840, a selective inhibitor of phosphodiesterase type IV (PDE IV), on the allergen induced asthmatic response. Am J Respir Crit Care Med (1996) 153:A347.
85. 3H] rolipram binding site: 3-Norbomyl-4-methoxyphenylmethylene oxindoles. Bioorg Med Chem Lett (1995) 5:1965-1968.
86. 3H] rolipram binding site. Bioorg Med Chem Lett (1995) 5:1969-1972.
87. Ward A, Clissold SP: Pentoxifylline: A review of its pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 34:50-97.
88. Schering-Plough and Chiroscience to develop new oral treatments for asthma and inflammatory diseases. MDIS Pharmaceutical & Medical News (1997).
89. V11294A. Drug Data Report (1998).
90. SB 207499 SmithKline Beecham phase change II, USA. R&D Focus Drug News 13 May 1996.
91. Schering highlights "research, search and development" Scrip (1997) 2228 10.
92. Togi H, Matsunaga M, Hirata A, Sato T, Kurahashi K, Kashimura H, Kurihara A, Suzuki H, Sato N: Effect of ME 3167 (rolipram) on psychiatric symptoms of post-stroke victims. Yakiri Chiryo (1997) 25:1171-1184.
93. Huizinga TWJ, Dijkmans BA, van der Velde EA, van de Pouw Kraan TC, Verweij CL, Breedveld FC: An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. (1996) Ann Rheumatic Dis 55:833-836.
94. Kevra MK, Dubovic BV, Kevra JS: Gastrointestinal tolerance to NSAIDs improvement due to pentoxifylline. Eur J Clin Pharmacol (1997) 52:A343.
95. CG-1088 is in Phase I trials Scrip (1997) 2226 22.
96. Kyorin Seiyaku (Irikura T, Nishino K, Hara S): Use of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine for preparing an anti-rheumatic agent. EP-00215438 (1987).